Body fluid analysis market to hit $3.65b on neurological and cancer demand

Speciality diagnostics widen across multiple body fluid categories in hospital laboratories.

The global body fluid analysis market will rise from $2.62b in 2026 to $3.65b in 2031, at a compound annual growth rate of 6.9%, according to a MarketsandMarkets report.

“Market growth is primarily driven by the increasing prevalence of neurological disorders, infectious diseases, cancer, and male reproductive health conditions that require specialised fluid-based diagnostics,” the report said.

The market covers diagnostic testing of speciality body fluids, including cerebrospinal fluid, pleural fluid, peritoneal fluid, synovial fluid, semen, and pericardial fluid.

The report said demand for early, accurate diagnosis, improved laboratory infrastructure, and higher healthcare investment in emerging economies is supporting adoption of automated, high-sensitivity body fluid analysis in hospitals and reference laboratories.

Asia-Pacific is projected to record the highest growth rate from 2026 to 2031, with China, Japan, and India representing key markets in the region, supported by hospital expansion and laboratory infrastructure development.

Clinical diagnostics accounted for 84.8% of applications in 2025, making it the largest segment, whilst cerebrospinal fluid held a 29.1% share by fluid type in the same year.

Consumables accounted for 70.4% of the product segment in 2025. These include reagent kits, assay panels, and stains used in testing workflows. Each specimen requires fresh reagents, which supports repeat demand across laboratories.

Immunoassay systems are projected to record the highest growth rate over the forecast period, reflecting increased use of biomarker-based testing in neurological, infectious, and inflammatory conditions.

“The body fluid analysis market, by technology, is divided into microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction, and other technologies,” the report said.

Automation in laboratory testing, including immunoassay systems and flow cytometry platforms, supports standardised and multi-parameter analysis across cerebrospinal, pleural, and peritoneal fluids.